

Rustem A Gafanov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6028514/publications.pdf>

Version: 2024-02-01

16
papers

3,065
citations

1306789

7
h-index

1372195

10
g-index

16
all docs

16
docs citations

16
times ranked

3906
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	13.9	2,319
2	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1563-1573.	5.1	466
3	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1029-1039.	0.8	145
4	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1020-1028.	0.8	83
5	KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 3291-3299.	1.1	22
6	Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2022, 82, 427-439.	0.9	15
7	Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 983-988.	2.0	11
8	Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection. <i>Onkourologiya</i> , 2019, 14, 139-149.	0.1	2
9	Metastatic castration-resistant prostate cancer: a current view on drug therapy and alternative tumor cell regulation. <i>Onkourologiya</i> , 2018, 14, 107-116.	0.1	1
10	An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia. <i>Onkourologiya</i> , 2020, 16, 90-101.	0.1	1
11	MODERN POSSIBILITIES OF THERAPY WITH INHIBITORS OF CONTROL POINTS IN METASTATIC UROTHELIAL CANCER. <i>Issledovaniya I Praktika V Medicine</i> , 2018, 5, 74-81.	0.1	0
12	Comparative analysis of indicators of erectile function in patients with localized prostate cancer after brachytherapy and radical prostatectomy. <i>Experimental and Clinical Urology</i> , 2019, 11, 50-53.	0.0	0
13	Experience of using atezolizumab in 1st line therapy of metastatic urothelial cancer. <i>Onkourologiya</i> , 2019, 15, 113-119.	0.1	0
14	Choice of treatment options for metastatic hormone-sensitive prostate cancer. <i>Meditsinskiy Sovet</i> , 2020, , 90-99.	0.1	0
15	Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?. <i>Onkourologiya</i> , 2020, 16, 29-37.	0.1	0
16	Chemoimmunotherapy in urothelial cancer: concurrent or sequential?. <i>Onkourologiya</i> , 2022, 17, 124-128.	0.1	0